Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 5 | -$1.58 | -$1.10 | -$1.34 |
| Q2 2026 | 5 | -$1.70 | $1.09 | $0.29 |
| Q3 2026 | 1 | -$1.53 | $0.04 | -$1.19 |
| Q4 2026 | 1 | -$0.90 | $0.02 | -$0.70 |
| Q1 2027 | 1 | -$1.37 | $0.04 | -$1.07 |
| Q2 2027 | 1 | -$1.16 | $0.03 | -$0.90 |
| Q3 2027 | 1 | -$0.13 | $0.00 | -$0.11 |
| Q4 2027 | 1 | -$1.46 | $0.04 | -$1.14 |
| Q1 2028 | 2 | -$0.12 | $0.00 | -$0.09 |
| Q2 2028 | 2 | -$0.17 | $0.00 | -$0.13 |
| Q3 2028 | 2 | -$0.15 | $0.00 | -$0.12 |
| Q4 2028 | 2 | -$0.17 | $0.00 | -$0.13 |
Regenxbio Inc last posted its earnings results on Thursday, March 5th, 2026. The company reported $-1.3 earnings per share for the quarter, missing analysts' consensus estimates of $-1.01 by $0.29. The company had revenue of 30.34 M for the quarter and had revenue of 170.44 M for the year. Regenxbio Inc has generated $-4 earnings per share over the last year ($-3.76 diluted earnings per share) and currently has a price-to-earnings ratio of -2.66. Regenxbio Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/05/2026 | Q4 2025 | -$1.01 | -$1.30 | -0.29 | $43.96 M | $30.34 M |
| 11/06/2025 | Q3 2025 | -$1.38 | -$1.20 | 0.18 | $24.82 M | $29.73 M |
| 08/07/2025 | Q2 2025 | -$1.13 | -$1.38 | -0.25 | $38.70 M | $21.36 M |
| 05/12/2025 | Q1 2025 | $0.41 | $0.12 | -0.29 | $107.89 M | $89.01 M |
| 03/13/2025 | Q4 2024 | -$1.27 | -$1.01 | 0.26 | $23.70 M | $21.21 M |
| 11/06/2024 | Q3 2024 | -$1.16 | -$1.17 | -0.01 | $23.63 M | $24.20 M |
| 08/01/2024 | Q2 2024 | -$1.29 | -$1.05 | 0.24 | $22.97 M | $22.30 M |
| 05/08/2024 | Q1 2024 | -$1.28 | -$1.38 | -0.1 | $23.52 M | $15.62 M |
| 02/27/2024 | Q4 2023 | -$1.27 | -$1.43 | -0.16 | N/A | $22.21 M |
| 11/08/2023 | Q3 2023 | -$1.44 | -$1.41 | 0.03 | N/A | $28.91 M |
| 08/02/2023 | Q2 2023 | -$1.26 | -$1.66 | -0.4 | N/A | $19.98 M |
| 05/03/2023 | Q1 2023 | -$1.52 | -$1.61 | -0.09 | N/A | $19.14 M |
| 02/28/2023 | Q4 2022 | -$1.48 | -$1.38 | 0.1 | N/A | $31.35 M |
| 11/03/2022 | Q3 2022 | -$1.55 | -$1.85 | -0.3 | N/A | $26.51 M |
| 08/03/2022 | Q2 2022 | -$1.44 | -$1.58 | -0.14 | N/A | $32.65 M |
| 05/04/2022 | Q1 2022 | -$1.29 | -$1.79 | -0.5 | N/A | $22.22 M |
| 03/01/2022 | Q4 2021 | $4.71 | $6.87 | 2.16 | N/A | $398.66 M |
| 11/02/2021 | Q3 2021 | -$0.87 | -$1.37 | -0.5 | N/A | $30.77 M |
| 08/09/2021 | Q2 2021 | -$1.08 | -$1.36 | -0.28 | N/A | $22.04 M |
| 05/05/2021 | Q1 2021 | -$1.13 | -$1.20 | -0.07 | N/A | $18.88 M |
The conference call for Regenxbio Inc's latest earnings report can be listened to online.
The conference call transcript for Regenxbio Inc's latest earnings report can be read online.
Regenxbio Inc (:RGNX) has a recorded annual revenue of $170.44 M.
Regenxbio Inc (:RGNX) has a recorded net income of $-193,878,000.Regenxbio Inc has generated $-3.76 earnings per share over the last four quarters.
Regenxbio Inc (:RGNX) has a price-to-earnings ratio of -2.66 and price/earnings-to-growth ratio is -0.35.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED